T790 M Resistance Expanded Access Trial

An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR) -Directed Therapy for Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) with T790M Resistance Mutation

Objective

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR-directed therapy and have evidence of a T790M mutation (T790M+).

 

Must have documented evidence of one or more activating EGFR mutations (excluding the exon 20 insertion mutation) and the T790M resistance mutation.

Prior treatment with an approved or experimental EGFR-directed therapy.

Requirement of therapy due to disease progression confirmed by radiologic and/or clinical assessment and/or intolerance to prior EGFR-directed therapy.

 

 

IRB Protocol Number

CO-1686-031

Contact

Judy Miller, RN CCRP at 406-435-7482
or jmiller4@billingsclinic.org